Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Vor Biopharma Inc (VOR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Vor Biopharma's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.71 -0.09    -5.00%
16:00:29 - Closed. Currency in USD ( Disclaimer )
After Hours
1.71
-0.00
-0.00%
16:02:44 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 348,333
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 1.70 - 1.83
Vor Biopharma 1.71 -0.09 -5.00%

Vor Biopharma Inc Company Profile

 
Get an in-depth profile of Vor Biopharma Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

133

Equity Type

ORD

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Contact Information

Address 100 Cambridgepark Drive Suite 101
Cambridge, 02140
United States
Phone 617 655 6580
Fax -

Top Executives

Name Age Since Title
Matthew R. Patterson 51 2020 Independent Chairman of the Board
David C. Lubner 59 2020 Independent Director
Robert Ang 48 2019 President, CEO & Director
Daniella Beckman 44 2020 Independent Director
Soheil Meshinchi - 2021 Scientific & Clinical Advisor
Olivier Danos 65 2021 Scientific & Clinical Advisor
Malcolm K. Brenner 71 2023 Scientific Advisor
Joshua Resnick 49 2019 Independent Director
Hans-Peter Kiem - - Scientific & Clinical Advisor
Sven Ante Lundberg 60 2019 Independent Director
Steven Devine - - Scientific & Clinical Advisor
Eric L. Sievers 59 - Scientific & Clinical Advisor
Robert J. Soiffer 65 - Scientific & Clinical Advisor
Saar Gill - 2023 Scientific Advisor
Pietro Genovese - 2023 Scientific Advisor
Siddhartha Mukherjee 53 - Scientific Founder & Chairman of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

VOR Comments

Write your thoughts about Vor Biopharma Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Tolga Ünal
Tolga Ünal Mar 20, 2024 4:54PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A solid gem.
Gerson Alarcon
Gerson Alarcon Feb 08, 2021 11:07AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this hasn't updated 😔
Gerson Alarcon
Gerson Alarcon Feb 06, 2021 9:12PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
In line for the ride 🚀🚀
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email